Trends in co-prescribing of renin-angiotensin system (RAS)-acting agents in France, Germany and the UK during 2001 -2012

Study type

• Study topic:
  Human medicinal product

  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Drug utilisation
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Other
• Non-interventional study design, other:
  Descriptive study

Study drug and medical condition

• Anatomical Therapeutic Chemical (ATC) code:
  (C09) AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

  AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
• Medical condition to be studied:
  Hypertension

  Diabetes mellitus

Population studied

• Short description of the study population:
  All patients with at least one consultation in the calendar year in question receiving a prescription of RAS-acting agents as recorded in the IMS Health databases in France, Germany and the UK.
• Age groups:
  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Special population of interest:
  Renal impaired
• Estimated number of subjects:
  18000000

Study design details

• Main study objective:
  To provide drug utilisation data on dual blockade of the renin-angiotensin system (RAS) by describing the extent and the pattern of co-prescription of different RAS-acting agents prescribed on the same day and by the same physician in France, Germany and the UK
• Outcomes:
  Estimation of prevalence of co-prescription of RAS-acting agents in France, Germany and the UK,Description of pattern of co-prescription of RAS-acting agents in France, Germany and the UK over time (2001-2012), Estimation of prevalence and pattern of RAS-acting agent co-prescription in patients with Diabetes Mellitus or with Chronic Kidney Disease.
• Data analysis plan:
  This analysis is descriptive in nature. In each country the following will be investigated:• Prevalence: number and percentage of patients prescribed any drug acting on RAS and with any co-prescription of these drugs in 2012:o In the general population included in the database,o In each of the following populations: patients treated with antihypertensive drugs, patients with diabetes and patients with chronic kidney disease.• Prescription pattern: percentage of patients prescribed with any drug acting on RAS and with any co-prescription of these drugs between 2001 and 2012:o In the general population included in the database,o In each of the two populations: patients with diabetes and patients with chronic kidney disease.Co-prescription will be defined as the prescription of different drug classes made on the same day and by the same physician.